key: cord-1015000-5orfmtto
authors: Masset, Christophe; Kerleau, Clarisse; Garandeau, Claire; Ville, Simon; Cantarovich, Diego; Hourmant, Maryvonne; Kervella, Delphine; Meurette, Aurélie; Guillot-Gueguen, Cécile; Guihard, Irène; Giral, Magali; Dantal, Jacques; Blancho, Gilles
title: A third injection of BNT162b2 mRNA Covid-19 vaccine in kidney transplant recipients improves the humoral immune response
date: 2021-08-30
journal: Kidney Int
DOI: 10.1016/j.kint.2021.08.017
sha: e5d995208da48be0ca766e6f566cdc8d8f2d0e45
doc_id: 1015000
cord_uid: 5orfmtto

nan

To the editors, Several reports have highlighted the poor humoral immune response of kidney transplant recipients following Covid mRNA vaccination compared to immunocompetent patients [1] [2] [3] .

Therefore, the French National Authority for Health has recommended the use of a third vaccine dose for immunosuppressed patients such as solid organ transplant recipients. We retrospectively assessed the humoral response of all kidney and pancreas transplant recipients vaccinated with BNT162b2 mRNA (Pfizer BioNTech) Covid-19 vaccine between January and May 2021 in our center. Patients with previous Covid-19 infection or positive prevaccination serology were excluded. The methods for detection of the anti-spike protein responses were dependent on laboratories' practices and included, chemiluminescent microparticle immunoassay (Abbott Architect®), chemiluminescence immunoassay (Siemens Atellica®), and electrochemiluminescence immunoassay (Roche Elecsys®)). Anti-spike (IgG) responses were assessed one month after the second and third injection, patients were considered positive if their anti-spike level was above the laboratory threshold. 456 patients had a serological assessment one month after the second injection of whom 227 were positive representing 49.7% of our cohort ( Table 1) . 10.7% of these patients had a positive anti-spike protein one month after the first injection. Multivariate regression analysis ( serological conversion following the third mRNA injection ( Figure 1A and Table 3 ). Among patients receiving a third dose, 85 had a serological assessment after both two and three J o u r n a l P r e -p r o o f injections, 34 of them (40%) became seropositive between the second and the third dose.

Magnitude of immune response was investigated in 71 patients who had serological assessment using electrochemiluminescence immunoassay (Roche Elecsys®) after two and three injections (Figure 1B and 1C) . Nearly all patients with a positive serology after the second mRNA vaccine had a very high titer of anti-spike antibody (> 250UI/l). Multivariate regression analysis ( Table 4 ) determined that lymphocyte count < 1500/mm 3 However, severe lymphopenia and impaired graft function remained as risk factors for nonserological response. In this particular situation, a fourth dose, with or without immunomodulation, could be discussed in order to improve the humoral response of this highly immunosuppressed population. These data will need confirmation from other series. 

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination

Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

Occurrence of severe COVID-19 in vaccinated transplant patients